National Patent Development Corp andBar-Ilan University of Israel said that their joint venturecorporation, Scientific Testing Inc, will begin a clinicaltrial in the U.S. of its immuno-augmenting compound, AS101, forthe treatment of Acquired Immune Deficiency Syndrome (AIDS).    The study will be conducted at the Institute ofImmunological Disorders (MD Anderson Hospital, Houston, Tex)under the direction of Dr Peter Mensell, pursuant to aninvestigational new drug application filed with the Food andDrug Administration, the company said.    The study, expected to begin in four to six weeks, isdesigned to test the effects of AS101 on about 30 AIDSpatients, National Patent said.    It added that AS101, a proprietary synthetic compoundinvented by Bar-Ilan University doctors, has shownimmuno-augmenting, anti-viral and anti-tumor activity inpreclinical animal testing, and immuno-augmenting activity in alimited number of AIDS patients in phase one foreign clinicaltests. Reuter&#3;